Name | 3-(2,3,4,5-tetrabromophenyl)prop-2-enoic acid |
---|---|
Synonyms |
(2E)-3-(2,3,4,5-tetrabromophenyl)prop-2-enoic acid
tetrabromocinnamic acid 2-Propenoic acid, 3-(2,3,4,5-tetrabromophenyl)-, (2E)- (2E)-3-(2,3,4,5-Tetrabromophenyl)acrylic acid |
Description | TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases[1][2]. |
---|---|
Related Catalog | |
Target |
CK2:110 nM (IC50) CK2:77 nM (Ki) |
In Vitro | TBCA (0-100 μM; 24 hours) shows a drastic effect on Jurkat cells viability[1]. TBCA also inhibits CK2 double mutant (Val66 Ile174) with an IC50 of 0.68 μM[1]. TBCA dose-dependently inhibits platelet aggregation and secretion induced by various agonists including 2-MeSADP, AYPGKF, SFLLRN, and CRP. TBCA also inhibits phosphorylation of PDK1, Akt, and GSK3β induced by AYPGKF[2]. Cell Viability Assay[1] Cell Line: Jurkat cells Concentration: 0-100 μM Incubation Time: 24 hours Result: The viability of Jurkat cells was reduced. |
References |
Density | 2.4±0.1 g/cm3 |
---|---|
Boiling Point | 490.8±45.0 °C at 760 mmHg |
Molecular Formula | C9H4Br4O2 |
Molecular Weight | 463.743 |
Flash Point | 250.6±28.7 °C |
Exact Mass | 459.694458 |
PSA | 37.30000 |
LogP | 5.28 |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.714 |